pre-IPO PHARMA

COMPANY OVERVIEW

Retrotope, a privately-held, clinical-stage pharmaceutical company, is creating a new category of drugs to treat degenerative diseases. Composed of proprietary compounds that are chemically stabilized forms of essential nutrients, these compounds are being studied as disease modifying therapies for many intractable diseases such as Parkinson's, Alzheimer's, neuromuscular diseases, and retinopathies.


LOCATION

  • Los Altos, CA, USA

  • THERAPEUTIC AREAS

  • Neurological DIsorders
  • Rare Diseases

  • WEBSITE

    https://www.retrotope.com


    CAREER WEBSITE

    https://www.retrotope.com/careers/


    SOCIAL MEDIA


    INVESTORS

    mehta-family-partners morningside-venture-investments timur-artemev


    PRESS RELEASES


    Oct 19, 2021

    Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit


    Oct 6, 2021

    Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD)


    Aug 11, 2021

    Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)


    Jun 30, 2021

    Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)


    Apr 21, 2021

    Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)


    For More Press Releases


    Google Analytics Alternative